TOP TEN perturbations for 39782_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39782_at
Selected probe(set): 200056_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39782_at (200056_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
IgA nephropathy study 8 / control glomerulus tissue
Relative Expression (log2-ratio):-2.3367872Number of Samples:20 / 20
| Experimental | IgA nephropathy study 8 |
| Hand-microdissected glomerular tissue samples derived from kidney biopsies of patients with IgA nephropathy (IgAN). Whole-core patient biopsies were obtained as part of routine renal biopsy procedures. | |
| Control | control glomerulus tissue |
| Hand-microdissected glomerular tissue samples derived from kidney biopsies of healthy living kidney transplant donors. The biopsies were taken after reperfusion in the kidney transplant recipient. |
brefeldin A study 1 (0.5ug/ml; p53HCT116) / untreated p53HCT116 cell sample
Relative Expression (log2-ratio):2.058938Number of Samples:2 / 3
| Experimental | brefeldin A study 1 (0.5ug/ml; p53HCT116) |
| Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | untreated p53HCT116 cell sample |
| Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
atopic dermatitis study 21 (lesional; whole skin) / normal skin tissue
Relative Expression (log2-ratio):-2.032425Number of Samples:5 / 6
| Experimental | atopic dermatitis study 21 (lesional; whole skin) |
| Lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %. | |
| Control | normal skin tissue |
| Full thickness skin samples isolated from healthy subjects by laser capture microdissection. |
atopic dermatitis study 21 (non-lesional; whole skin) / normal skin tissue
Relative Expression (log2-ratio):-1.9181108Number of Samples:5 / 6
| Experimental | atopic dermatitis study 21 (non-lesional; whole skin) |
| Non-lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %. | |
| Control | normal skin tissue |
| Full thickness skin samples isolated from healthy subjects by laser capture microdissection. |
atopic dermatitis study 12 (non-lesional; adults) / atopic dermatitis study 12 (non-lesional; children)
Relative Expression (log2-ratio):-1.8914309Number of Samples:20 / 19
| Experimental | atopic dermatitis study 12 (non-lesional; adults) |
| Unaffected skin biopsy samples from adult patients (age range 18-73 years) with long-standing atopic dermatitis. | |
| Control | atopic dermatitis study 12 (non-lesional; children) |
| Unaffected buttock skin biopsy samples from pediatric patients (age range 3 months-5 years) with early-onset atopic dermatitis. All patients had moderate-to-severe disease (SCORAD score: mean, 57.8; range, 33-84) with recent-onset (within the previous 6 months). Systemic immunosuppressants within the past 4 weeks, topical steroids or immunomodulators within 1 week, or moisturizers within 12 hours before evaluation were restricted. Patients with active skin infections were excluded. |
atopic dermatitis study 12 (lesional; adults) / atopic dermatitis study 12 (lesional; children)
Relative Expression (log2-ratio):-1.8643703Number of Samples:20 / 18
| Experimental | atopic dermatitis study 12 (lesional; adults) |
| Lesional skin biopsy samples from adult patients (age range 18-73 years) with long-standing atopic dermatitis. | |
| Control | atopic dermatitis study 12 (lesional; children) |
| Lesional popliteal skin biopsy samples from pediatric patients (age range 3 months-5 years) with early-onset atopic dermatitis. All biopsy specimens were from chronic lesions present for more than 72 hours. All patients had moderate-to-severe disease with recent-onset (within the previous 6 months). Systemic immunosuppressants within the past 4 weeks, topical steroids or immunomodulators within 1 week, or moisturizers within 12 hours before evaluation were restricted. Patients with active skin infections were excluded. |
ovarian tumor study 11 (high grade) / ovarian tumor study 11 (low grade)
Relative Expression (log2-ratio):1.8417606Number of Samples:22 / 11
| Experimental | ovarian tumor study 11 (high grade) |
| Human microdissected tumor cells from the ovary of patients with high grade serous carcinoma. | |
| Control | ovarian tumor study 11 (low grade) |
| Human microdissected tumor cells from the ovary of patients with low grade serous carcinoma. |
cadmium study 1 (brief) / untreated NPrEC cell sample
Relative Expression (log2-ratio):-1.8125706Number of Samples:2 / 2
| Experimental | cadmium study 1 (brief) |
| After 72h of starvation, NPrEC cells were briefly exposed to 2.5 uM CdCl2. ATC code:--- | |
| Control | untreated NPrEC cell sample |
| After 72h of starvation, NPrEC cells were briefly exposed to complete medium without CdCl2. |
kidney transplantation study 15 (8 week) / normal monocyte (CD14+) sample
Relative Expression (log2-ratio):-1.7763643Number of Samples:2 / 5
| Experimental | kidney transplantation study 15 (8 week) |
| CD14+ monocyte samples derived from kidney transplant patients 8 weeks post-transplantation. Samples were collected 8 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH). | |
| Control | normal monocyte (CD14+) sample |
| CD14+ monocyte samples derived from healthy control subjects. |
ovarian tumor study 11 (low grade) / ovarian tumor study 11 (borderline)
Relative Expression (log2-ratio):-1.7748022Number of Samples:11 / 8
| Experimental | ovarian tumor study 11 (low grade) |
| Human microdissected tumor cells from the ovary of patients with low grade serous carcinoma. | |
| Control | ovarian tumor study 11 (borderline) |
| Human microdissected tumor cells from the ovary of patients with low-malignant (borderline) tumors of the ovary. |
Organism: Homo sapiens
Gene: 39782_at
Selected probe(set): 200056_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39782_at (200056_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
IgA nephropathy study 8 / control glomerulus tissue
Relative Expression (log2-ratio):-2.3367872Number of Samples:20 / 20
| Experimental | IgA nephropathy study 8 |
| Hand-microdissected glomerular tissue samples derived from kidney biopsies of patients with IgA nephropathy (IgAN). Whole-core patient biopsies were obtained as part of routine renal biopsy procedures. | |
| Control | control glomerulus tissue |
| Hand-microdissected glomerular tissue samples derived from kidney biopsies of healthy living kidney transplant donors. The biopsies were taken after reperfusion in the kidney transplant recipient. |
brefeldin A study 1 (0.5ug/ml; p53HCT116) / untreated p53HCT116 cell sample
Relative Expression (log2-ratio):2.058938Number of Samples:2 / 3
| Experimental | brefeldin A study 1 (0.5ug/ml; p53HCT116) |
| Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | untreated p53HCT116 cell sample |
| Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
atopic dermatitis study 21 (lesional; whole skin) / normal skin tissue
Relative Expression (log2-ratio):-2.032425Number of Samples:5 / 6
| Experimental | atopic dermatitis study 21 (lesional; whole skin) |
| Lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %. | |
| Control | normal skin tissue |
| Full thickness skin samples isolated from healthy subjects by laser capture microdissection. |
atopic dermatitis study 21 (non-lesional; whole skin) / normal skin tissue
Relative Expression (log2-ratio):-1.9181108Number of Samples:5 / 6
| Experimental | atopic dermatitis study 21 (non-lesional; whole skin) |
| Non-lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %. | |
| Control | normal skin tissue |
| Full thickness skin samples isolated from healthy subjects by laser capture microdissection. |
atopic dermatitis study 12 (non-lesional; adults) / atopic dermatitis study 12 (non-lesional; children)
Relative Expression (log2-ratio):-1.8914309Number of Samples:20 / 19
| Experimental | atopic dermatitis study 12 (non-lesional; adults) |
| Unaffected skin biopsy samples from adult patients (age range 18-73 years) with long-standing atopic dermatitis. | |
| Control | atopic dermatitis study 12 (non-lesional; children) |
| Unaffected buttock skin biopsy samples from pediatric patients (age range 3 months-5 years) with early-onset atopic dermatitis. All patients had moderate-to-severe disease (SCORAD score: mean, 57.8; range, 33-84) with recent-onset (within the previous 6 months). Systemic immunosuppressants within the past 4 weeks, topical steroids or immunomodulators within 1 week, or moisturizers within 12 hours before evaluation were restricted. Patients with active skin infections were excluded. |
atopic dermatitis study 12 (lesional; adults) / atopic dermatitis study 12 (lesional; children)
Relative Expression (log2-ratio):-1.8643703Number of Samples:20 / 18
| Experimental | atopic dermatitis study 12 (lesional; adults) |
| Lesional skin biopsy samples from adult patients (age range 18-73 years) with long-standing atopic dermatitis. | |
| Control | atopic dermatitis study 12 (lesional; children) |
| Lesional popliteal skin biopsy samples from pediatric patients (age range 3 months-5 years) with early-onset atopic dermatitis. All biopsy specimens were from chronic lesions present for more than 72 hours. All patients had moderate-to-severe disease with recent-onset (within the previous 6 months). Systemic immunosuppressants within the past 4 weeks, topical steroids or immunomodulators within 1 week, or moisturizers within 12 hours before evaluation were restricted. Patients with active skin infections were excluded. |
ovarian tumor study 11 (high grade) / ovarian tumor study 11 (low grade)
Relative Expression (log2-ratio):1.8417606Number of Samples:22 / 11
| Experimental | ovarian tumor study 11 (high grade) |
| Human microdissected tumor cells from the ovary of patients with high grade serous carcinoma. | |
| Control | ovarian tumor study 11 (low grade) |
| Human microdissected tumor cells from the ovary of patients with low grade serous carcinoma. |
cadmium study 1 (brief) / untreated NPrEC cell sample
Relative Expression (log2-ratio):-1.8125706Number of Samples:2 / 2
| Experimental | cadmium study 1 (brief) |
| After 72h of starvation, NPrEC cells were briefly exposed to 2.5 uM CdCl2. ATC code:--- | |
| Control | untreated NPrEC cell sample |
| After 72h of starvation, NPrEC cells were briefly exposed to complete medium without CdCl2. |
kidney transplantation study 15 (8 week) / normal monocyte (CD14+) sample
Relative Expression (log2-ratio):-1.7763643Number of Samples:2 / 5
| Experimental | kidney transplantation study 15 (8 week) |
| CD14+ monocyte samples derived from kidney transplant patients 8 weeks post-transplantation. Samples were collected 8 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH). | |
| Control | normal monocyte (CD14+) sample |
| CD14+ monocyte samples derived from healthy control subjects. |
ovarian tumor study 11 (low grade) / ovarian tumor study 11 (borderline)
Relative Expression (log2-ratio):-1.7748022Number of Samples:11 / 8
| Experimental | ovarian tumor study 11 (low grade) |
| Human microdissected tumor cells from the ovary of patients with low grade serous carcinoma. | |
| Control | ovarian tumor study 11 (borderline) |
| Human microdissected tumor cells from the ovary of patients with low-malignant (borderline) tumors of the ovary. |